C
nonalcoholic fatty liver disease
Comorbid ConditionsDisease / conditionriskpartially modifiable
11
evidence score
Also known as: Nonalcoholic fatty liver disease (NAFLD)
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 3meta-analyses: 0trials: 8.4genetic: 0MR bonus:
References (1)
0 meta-analyses / systematic reviews- Nonalcoholic fatty liver disease and cardiovascular disease. — World journal of gastroenterology 2014 · PMID 25024598
Clinical trials (6)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT07238985 | Evaluating the Safety and Efficacy of Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease Patients. | RECRUITING | INTERVENTIONAL | Standard therapy, Cilostazol |
| NCT05720702 | A Feasibility Trial of One-carbon Metabolism Cofactor Supplements for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) | COMPLETED | INTERVENTIONAL | homocysteine (Hcy) lowering supplements |
| NCT04976283 | Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial | UNKNOWN | INTERVENTIONAL | Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin |
| NCT01355575 | RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? | TERMINATED | INTERVENTIONAL | Rifaximin |
| NCT04820556 | The Development of Preventive Methods for Chronic Noncommunicable Diseases Based on Modulation of Gut Microbiota Composition and Function | COMPLETED | OBSERVATIONAL | |
| NCT04774302 | Study of Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With Nonalcoholic Fatty Liver Disease | COMPLETED | OBSERVATIONAL |
Genetic associations (0)
None linked.